\nEstablishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women\u2019s health, initially in the breast aesthetics and reconstruction market, today announced publication of its 2020 Corporate Social Responsibility annual review to coincide with the third anniversary of the company\u2019s public listing on NASDAQ.\n<\/p>\n
\n\u201cAs a publicly traded company, we are already subject to the highest standards of governance and compliance, but we are taking it a step further with our work to create ambitious sustainability goals for the coming decade,\u201d said Juan Jos\u00e9 Chac\u00f3n-Quir\u00f3s, Founder and CEO of Establishment Labs. \u201cWe will continue to report on our progress according to the 2030 UN Sustainable Development Goals (SDGs) and benchmark our company with our medical device and aesthetic peers and across other industries as we look for opportunities to improve further. On top of delivering on our financial and commercial commitments, it is clear to us that by making sustainability the core of our business, we will have many opportunities to create value for all our stakeholders and to be recognized as a leader in women\u2019s health.\u201d\n<\/p>\n
\nAmong the topics included in this year\u2019s review:\n<\/p>\n
- \n
- \nA presentation of the company\u2019s value map, stakeholders, and materiality framework, including an elevation of Women\u2019s Health and Well-being<\/i> to a key materiality topic alongside Environment<\/i>, Employees<\/i>, and Governance<\/i>.\n<\/li>\n<\/ul>\n
- \n
- \nAn assessment of the company\u2019s continued environmental efforts, including the recertification of its headquarters and manufacturing facilities as carbon neutral.\n<\/li>\n<\/ul>\n
- \n
- \nHighlights from the company\u2019s efforts in promoting women\u2019s health and well-being, including its patient advocacy efforts and its support of Breast Cancer Awareness, International Day of Women & Girls in Science, International Women\u2019s Day, and other relevant programs.\n<\/li>\n<\/ul>\n
- \n
- \nAn overview of collaborative research efforts with institutions around the globe, as well as efforts to share the learnings with relevant audiences through medical education and patient engagement.\n<\/li>\n<\/ul>\n
- \n
- \nA description of the company\u2019s efforts to nurture its corporate culture, including ensuring a safe work environment during the COVID-19 pandemic and ongoing training and support programs.\n<\/li>\n<\/ul>\n
- \n
- \nA review of the company\u2019s 2020 financial performance, its quality and regulatory activities, and an update on post-market surveillance clinical data.\n<\/li>\n<\/ul>\n
\nThe 2020 edition is the second publication of Establishment Labs\u2019 Corporate Social Responsibility annual review. The current and previous editions of the annual review can be found on the company\u2019s website at: https:\/\/establishmentlabs.com\/corporate-sustainability\/<\/a>.\n<\/p>\n
About Establishment Labs<\/span><\/b><\/p>\n
\nEstablishment Labs Holdings Inc. is global medical technology company dedicated to improving the health and wellness of women around the globe. The company\u2019s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants\u00ae that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 1.6 million Motiva Implants\u00ae have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora\u00ae tissue expander and Motiva MIA\u00ae, the company\u2019s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant\u00ae and began a clinical trial to support regulatory approval in the United States. Motiva Implants\u00ae are manufactured at the company\u2019s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com<\/a>.\n<\/p>\n
Forward-Looking Statements<\/span><\/b><\/p>\n
\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d). You can find many (but not all) of these statements by looking for words such as \u201capproximates,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cintends to,\u201d \u201cwould,\u201d \u201cwill,\u201d \u201cmay\u201d or other similar expressions in this press release. Factors, among others, that could cause actual results and events to differ materially from those described in any forward-looking statements include risks and uncertainties relating to: our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product offerings; the rate of adoption of our products by healthcare providers or other customers; the success of our marketing initiatives; the safe and effective use of our products; our ability to protect our intellectual property; our future expansion plans and capital allocation; our ability to expand upon and\/or secure sources of credit or capital; our ability to develop and maintain relationships with qualified suppliers to avoid a significant interruption in our supply chains; our ability to attract and retain key personnel; our ability to scale our operations to meet market demands; the effect on our business of existing and new regulatory requirements; and other economic and competitive factors. Any statements that refer to projections of our future financial or operating performance, anticipated trends in our business, our goals, strategies, focus and plans, and other characterizations of future events or circumstances, including statements expressing general optimism about future operating results, related to the company\u2019s performance are forward-looking statements. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this report, or that we may make orally or in writing from time to time, are expressions of our beliefs and expectations based on currently available information at the time such statements are made. Such statements are based on assumptions, and the actual outcome will be affected by known and unknown risks, trends, uncertainties, and factors that are beyond our control. Although we believe that our assumptions are reasonable, we cannot guarantee future performance, and some will inevitably prove to be incorrect. As a result, our actual future results and the timing of events may differ from our expectations, and those differences may be material. Factors that could cause or contribute to these differences include, among others, those risks and uncertainties discussed in the company\u2019s annual report on Form 10-K filed on March 15, 2021, quarterly reports on Form 10-Q, and other filings made by the company with the Securities and Exchange Commission. The risks included in those documents are not exhaustive, and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for us to predict all such risk factors, nor can we assess the impact of all such risk factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We are not undertaking any obligation to update any forward-looking statements. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.\n<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210720006167\/en\/<\/a><\/span><\/p>\n
Investor\/Media Contact:
\n<\/b>
Raj Denhoy
\n
415-828-1044
\n
rdenhoy@establishmentlabs.com<\/a><\/p>\nKEYWORDS:<\/b> United States North America California<\/p>\n
INDUSTRY KEYWORDS:<\/b> Surgery Medical Devices Women Consumer Health<\/p>\n
- \nA review of the company\u2019s 2020 financial performance, its quality and regulatory activities, and an update on post-market surveillance clinical data.\n<\/li>\n<\/ul>\n
- \nA description of the company\u2019s efforts to nurture its corporate culture, including ensuring a safe work environment during the COVID-19 pandemic and ongoing training and support programs.\n<\/li>\n<\/ul>\n
- \nAn overview of collaborative research efforts with institutions around the globe, as well as efforts to share the learnings with relevant audiences through medical education and patient engagement.\n<\/li>\n<\/ul>\n
- \nHighlights from the company\u2019s efforts in promoting women\u2019s health and well-being, including its patient advocacy efforts and its support of Breast Cancer Awareness, International Day of Women & Girls in Science, International Women\u2019s Day, and other relevant programs.\n<\/li>\n<\/ul>\n
- \nAn assessment of the company\u2019s continued environmental efforts, including the recertification of its headquarters and manufacturing facilities as carbon neutral.\n<\/li>\n<\/ul>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20210720006167\/en\/892840\/3\/el-logo-2018.jpg\"){kind=logo}
<\/td>\n<\/tr>\n